NASDAQ:VTVT vTv Therapeutics (VTVT) News Today $0.46 +0.01 (+2.22%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$0.44▼$0.4650-Day Range$0.42▼$0.7452-Week Range$0.41▼$1.05Volume51,916 shsAverage Volume135,219 shsMarket Capitalization$48.11 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19finance.yahoo.com - September 27 at 10:38 AMCantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancerfinance.yahoo.com - September 26 at 11:35 AMvTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.comamericanbankingnews.com - September 24 at 3:20 AMCANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMAfinance.yahoo.com - September 18 at 10:26 AMIs vTv Therapeutics Inc (VTVT) Modestly Undervalued?finance.yahoo.com - August 24 at 6:06 PMvTv Therapeutics reports $5.6 million net loss as prepares for reverse stock split to remain on Nasdaqfinance.yahoo.com - August 16 at 4:23 PMvTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Updatefinanznachrichten.de - August 12 at 8:18 AMvTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - August 11 at 5:16 PMCantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancerfinance.yahoo.com - August 10 at 11:34 AMNearly half of U.S. adults want weight-loss drugs – KFF pollmsn.com - August 6 at 10:58 PMVTVT - vTv Therapeutics Inc.finance.yahoo.com - July 12 at 12:55 PMvTv Therapeutics Inc - (VTVT) Price Target Decreased by 33.33% to 2.04msn.com - July 6 at 10:29 PMvTv Therapeutics Partner Licenses Exclusive Rights to Intellectual Property for Azeliragonmarketwatch.com - June 16 at 12:16 PMvTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as atmcnet.com - June 16 at 12:16 PMvTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Declinefinance.yahoo.com - June 16 at 12:16 PMCANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTONfinance.yahoo.com - June 15 at 10:25 AMAs it advances its Type 1 Diabetes treatment, vTv Therapeutics increases cash position, decreases net loss in Q1bizjournals.com - June 6 at 4:47 PMvTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticalsfinance.yahoo.com - May 24 at 2:17 PMvTv Therapeutics Inc.: vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Updatefinanznachrichten.de - May 12 at 8:33 AMvTv Therapeutics Insider Ups Holding During Yearfinance.yahoo.com - May 12 at 8:33 AMvTv Therapeutics Insider Ups Holding During Year \finance.yahoo.com - May 12 at 8:33 AMvTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - May 11 at 8:53 PMvTv Therapeutics Inc Class Amorningstar.com - April 28 at 9:27 PMCantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19finance.yahoo.com - April 20 at 12:51 PMPromising Upsides on these Biotech Penny Stocksmsn.com - April 18 at 6:07 PMPromising Upsides on these Biotech Penny Stocks (VTVT)marketbeat.com - April 18 at 8:17 AM3 Pharma Stocks That Could Benefit from Global Healthcare Trendsfinance.yahoo.com - March 25 at 9:48 AMvTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Updatefinance.yahoo.com - March 6 at 7:21 PMCantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastasesfinance.yahoo.com - March 6 at 8:21 AMvTv Therapeutics (NASDAQ:VTVT) investors are sitting on a loss of 88% if they invested five years agofinance.yahoo.com - March 3 at 6:34 AMCantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastomafinance.yahoo.com - February 27 at 11:27 PMElizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeuticsfinance.yahoo.com - February 1 at 8:33 PMVTVT.PH - | Stock Price & Latest News | Reutersreuters.com - January 31 at 11:39 PMFY2023 Earnings Forecast for vTv Therapeutics Inc. (NASDAQ:VTVT) Issued By Cantor Fitzgeraldmarketbeat.com - January 23 at 1:43 AMPrivate equity firms in vTv Therapeutics Inc. (NASDAQ:VTVT) are its biggest bettors, and their bets paid off as stock gained 21% last weekfinance.yahoo.com - January 20 at 2:47 PMvTv Therapeutics names biotechnology industry veteran Steven Tuch as CFObizjournals.com - January 12 at 9:26 AMCANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMAfinance.yahoo.com - January 9 at 10:32 AMVtv Therapeuticsforbes.com - January 5 at 2:37 PMvTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officerfinance.yahoo.com - December 13 at 11:44 AMTrade Alert: The Independent Director Of vTv Therapeutics Inc. (NASDAQ:VTVT), John Fry, Has Just Spent US$51k Buying A Few More Sharesfinance.yahoo.com - December 3 at 8:26 AMvTv Therapeutics Board Member Makes $50K Stock Purchasebenzinga.com - December 1 at 11:23 AMvTv Therapeutics (NASDAQ:VTVT) Research Coverage Started at StockNews.commarketbeat.com - November 17 at 9:00 AMThree months after leadership change, vTv Therapeutics reports cash of $15.3 million and net loss of $4.3 million in Q3finance.yahoo.com - November 15 at 5:50 PMvTv Therapeutics Inc.: vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Updatefinanznachrichten.de - November 11 at 1:25 PMvTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - November 10 at 10:23 PMVTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimatesfinance.yahoo.com - November 10 at 10:23 PMvTv Therapeutics (NASDAQ:VTVT shareholders incur further losses as stock declines 17% this week, taking five-year losses to 84%finance.yahoo.com - September 23 at 8:34 AMVTVT vTv Therapeutics Inc.seekingalpha.com - September 22 at 8:28 PMThis Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Saysfinance.yahoo.com - August 19 at 8:04 PMAfter third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 million net loss in Q2bizjournals.com - August 19 at 9:19 AM Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address VTVT Media Mentions By Week VTVT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTVT News Sentiment▼0.870.86▲Average Medical News Sentiment VTVT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTVT Articles This Week▼41▲VTVT Articles Average Week Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LGVN News ASMB News HUGE News SLGL News CELU News SLS News AGLE News IPA News MEIP News DNTH News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:VTVT) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.